Literature DB >> 21340489

Tyrosinemia type I: long-term outcome in a patient treated with doses of NTBC lower than recommended.

Patrizia D'Eufemia, Mauro Celli, Martina Tetti, Roberto Finocchiaro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21340489     DOI： 10.1007/s00431-011-1419-4

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


× No keyword cloud information.
  2 in total

Review 1.  Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).

Authors:  E Holme; S Lindstedt
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

2.  Clinical practice. NTBC therapy for tyrosinemia type 1: how much is enough?

Authors:  Hanaa El-Karaksy; Mohmmad Rashed; Rokaya El-Sayed; Mona El-Raziky; Nehal El-Koofy; Manal El-Hawary; Osama Al-Dirbashi
Journal:  Eur J Pediatr       Date:  2009-10-31       Impact factor: 3.183
  2 in total
  3 in total

1.  Single dose NTBC-treatment of hereditary tyrosinemia type I.

Authors:  A Schlune; E Thimm; D Herebian; U Spiekerkoetter
Journal:  J Inherit Metab Dis       Date:  2012-02-04       Impact factor: 4.982

2.  Dose-Finding Studies Among Orphan Drugs Approved in the EU: A Retrospective Analysis.

Authors:  Yvonne Schuller; Christine Gispen-de Wied; Carla E M Hollak; Hubertus G M Leufkens; Violeta Stoyanova-Beninska
Journal:  J Clin Pharmacol       Date:  2018-09-07       Impact factor: 3.126

Review 3.  Recommendations for the management of tyrosinaemia type 1.

Authors:  Corinne de Laet; Carlo Dionisi-Vici; James V Leonard; Patrick McKiernan; Grant Mitchell; Lidia Monti; Hélène Ogier de Baulny; Guillem Pintos-Morell; Ute Spiekerkötter
Journal:  Orphanet J Rare Dis       Date:  2013-01-11       Impact factor: 4.123
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.